200
Participants
Start Date
March 7, 2025
Primary Completion Date
January 15, 2027
Study Completion Date
September 15, 2027
VRC07-523LS 400mg
Intravenous infusion (IV)
PGT121.414.LS 400mg
IV infusion
PGDM1400LS 400mg
IV infusion
VRC07-523LS 3200mg
IV infusion
PGT121.414.LS 1600mg
IV infusion
PGDM1400LS 1600mg
IV infusion
NOT_YET_RECRUITING
ACSA CRS, Iquitos
NOT_YET_RECRUITING
Perinatal HIV Research Unit (PHRU), Johannesburg
NOT_YET_RECRUITING
Chatsworth CRS, Chatsworth
NOT_YET_RECRUITING
Groote Schuur HIV CRS, Cape Town
RECRUITING
Columbia P&S CRS, New York
NOT_YET_RECRUITING
Via Libre, Lima
NOT_YET_RECRUITING
Citbm Crs, Callao
NOT_YET_RECRUITING
University of Pittsburgh CRS (Site 1001), Pittsburgh
RECRUITING
Penn Prevention CRS, Philadelphia
RECRUITING
Chapel Hill CRS (Site #3201), Chapel Hill
RECRUITING
The Hope Clinic of the Emory Vaccine Research Center; Emory University, Decatur
RECRUITING
Alabama CRA (Site #31788), Birmingham
RECRUITING
Vanderbilt Vaccine (VV) CRS, Nashville
RECRUITING
Bridge HIV, San Francisco Department of Public Health, San Francisco
RECRUITING
Seattle Vaccine and Prevention CRS (Site ID# 30331), Seattle
RECRUITING
Brigham and Women's Hospital Vaccine CRS (BWH VCRS), Boston
NOT_YET_RECRUITING
Fenway Health, Boston
RECRUITING
BIDMC VCRS (Site ID# 32077), Boston
NOT_YET_RECRUITING
Instituto de Pesquisa Clinica Evandro Chagas (IPEC) CRS, Rio de Janeiro
NOT_YET_RECRUITING
Setshaba Research Centre, Soshanguve-H
National Institutes of Health (NIH)
NIH
Department of Health and Human Services
FED
Dale and Betty Bumpers Vaccine Research Center (VRC)
UNKNOWN
National Institute of Allergy and Infectious Diseases (NIAID)
NIH